

Giovanni Davi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3853268/publications.pdf>

Version: 2024-02-01

97
papers

8,959
citations

53751

45
h-index

39638

94
g-index

99
all docs

99
docs citations

99
times ranked

10955
citing authors

#	ARTICLE	IF	CITATIONS
1	Platelet Activation and Atherothrombosis. <i>New England Journal of Medicine</i> , 2007, 357, 2482-2494.	13.9	1,831
2	Thromboxane Biosynthesis and Platelet Function in Type II Diabetes Mellitus. <i>New England Journal of Medicine</i> , 1990, 322, 1769-1774.	13.9	565
3	Platelet Activation in Obese Women. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 2008.	3.8	484
4	In Vivo Formation of 8-Epi-Prostaglandin F ₂ Is Increased in Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 3230-3235.	1.1	356
5	Lipid Peroxidation in Diabetes Mellitus. <i>Antioxidants and Redox Signaling</i> , 2005, 7, 256-268.	2.5	303
6	Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1013-1020.	1.2	237
7	Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays. <i>Journal of the American College of Cardiology</i> , 2009, 53, 667-677.	1.2	234
8	Association Between Enhanced Soluble CD40L and Prothrombotic State in Hypercholesterolemia. <i>Circulation</i> , 2002, 106, 399-402.	1.6	217
9	The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1220-1230.	1.9	211
10	Diabetes mellitus and thrombosis. <i>Thrombosis Research</i> , 2012, 129, 371-377.	0.8	195
11	Platelet activation in obesity and metabolic syndrome. <i>Obesity Reviews</i> , 2012, 13, 27-42.	3.1	188
12	Soluble Forms of RAGE in Human Diseases: Clinical and Therapeutical Implications. <i>Current Medicinal Chemistry</i> , 2009, 16, 940-952.	1.2	162
13	Soluble forms of RAGE in internal medicine. <i>Internal and Emergency Medicine</i> , 2009, 4, 389-401.	1.0	154
14	Enhanced Lipid Peroxidation and Platelet Activation in the Early Phase of Type 1 Diabetes Mellitus. <i>Circulation</i> , 2003, 107, 3199-3203.	1.6	131
15	Nutraceuticals in Diabetes and Metabolic Syndrome. <i>Cardiovascular Therapeutics</i> , 2010, 28, 216-226.	1.1	128
16	Soluble RAGE in type 2 diabetes: Association with oxidative stress. <i>Free Radical Biology and Medicine</i> , 2007, 43, 511-518.	1.3	125
17	Inflammation, insulin resistance, and obesity. <i>Current Atherosclerosis Reports</i> , 2004, 6, 424-431.	2.0	120
18	Insulin Resistance as a Determinant of Platelet Activation in Obese Women. <i>Journal of the American College of Cardiology</i> , 2006, 48, 2531-2538.	1.2	114

#	ARTICLE	IF	CITATIONS
19	Oxidative stress in chronic vascular disease: From prediction to prevention. <i>Vascular Pharmacology</i> , 2015, 74, 23-37.	1.0	113
20	Decreased plasma soluble RAGE in patients with hypercholesterolemia: Effects of statins. <i>Free Radical Biology and Medicine</i> , 2007, 43, 1255-1262.	1.3	110
21	Association of Inflammation Markers with Impaired Insulin Sensitivity and Coagulative Activation in Obese Healthy Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 5321-5326.	1.8	106
22	Thromboxane-Dependent CD40 Ligand Release in Type 2 Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2006, 47, 391-397.	1.2	102
23	The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. <i>Blood</i> , 2010, 115, 1054-1061.	0.6	100
24	Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1989, 992, 66-70.	1.1	95
25	In Vivo Lipid Peroxidation and Platelet Activation in Cystic Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 162, 1195-1201.	2.5	91
26	Determinants of F2-isoprostane biosynthesis and inhibition in man. <i>Chemistry and Physics of Lipids</i> , 2004, 128, 149-163.	1.5	85
27	Platelets and diabetes mellitus. <i>Prostaglandins and Other Lipid Mediators</i> , 2015, 120, 28-39.	1.0	84
28	Biomarkers of platelet activation in acute coronary syndromes. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1109-1123.	1.8	81
29	Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A "state-of-the-art" paper. <i>European Heart Journal</i> , 2014, 35, 2213-2223.	1.0	78
30	Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. <i>Atherosclerosis</i> , 2011, 214, 122-128.	0.4	77
31	Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: impact on mediators and mechanisms of the inflammatory response. <i>FASEB Journal</i> , 2010, 24, 3970-3980.	0.2	75
32	Determinants of platelet activation in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2007, 28, 336-342.	1.5	74
33	Isoprostane formation and inhibition in atherothrombosis. <i>Current Opinion in Pharmacology</i> , 2005, 5, 198-203.	1.7	71
34	Microparticles as new markers of cardiovascular risk in diabetes and beyond. <i>Thrombosis and Haemostasis</i> , 2016, 116, 220-234.	1.8	70
35	Effects of Liraglutide on Weight Loss, Fat Distribution, and β -Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes. <i>Diabetes Care</i> , 2017, 40, 1556-1564.	4.3	69
36	Decreased <i>in vivo</i> oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects. <i>Diabetes/Metabolism Research and Reviews</i> , 2008, 24, 231-237.	1.7	66

#	ARTICLE	IF	CITATIONS
37	Platelet Function in Health and Disease: from Molecular Mechanisms, Redox Considerations to Novel Therapeutic Opportunities. <i>Antioxidants and Redox Signaling</i> , 2012, 17, 1447-1485.	2.5	57
38	CD40 Ligand and MCP-1 as Predictors of Cardiovascular Events in Diabetic Patients with Stroke. <i>Journal of Atherosclerosis and Thrombosis</i> , 2009, 16, 707-713.	0.9	56
39	A novel flow cytometric approach to distinguish circulating endothelial cells from endothelial microparticles: Relevance for the evaluation of endothelial dysfunction. <i>Journal of Immunological Methods</i> , 2012, 380, 16-22.	0.6	56
40	Determinants of Increased Cardiovascular Disease in Obesity and Metabolic Syndrome. <i>Current Medicinal Chemistry</i> , 2011, 18, 5267-5280.	1.2	55
41	Physical exercise increases urinary excretion of lipoxin A ₄ and related compounds. <i>Journal of Applied Physiology</i> , 2003, 94, 2237-2240.	1.2	53
42	Circulating Dickkopf-1 in Diabetes Mellitus: Association With Platelet Activation and Effects of Improved Metabolic Control and Low-Dose Aspirin. <i>Journal of the American Heart Association</i> , 2014, 3, .	1.6	53
43	Plasma levels of soluble CD36, platelet activation, inflammation, and oxidative stress are increased in type 2 diabetic patients. <i>Free Radical Biology and Medicine</i> , 2012, 52, 1318-1324.	1.3	51
44	Thromboxane Receptors Antagonists and/or Synthase Inhibitors. <i>Handbook of Experimental Pharmacology</i> , 2012, , 261-286.	0.9	50
45	Oxidant Stress and Platelet Activation in Hypercholesterolemia. <i>Antioxidants and Redox Signaling</i> , 2004, 6, 747-756.	2.5	48
46	Arterial stiffness and sedentary lifestyle: Role of oxidative stress. <i>Vascular Pharmacology</i> , 2016, 79, 1-5.	1.0	45
47	Oxidative stress-related mechanisms affecting response to aspirin in diabetes mellitus. <i>Free Radical Biology and Medicine</i> , 2015, 80, 101-110.	1.3	44
48	Italian intersociety consensus on DOAC use in internal medicine. <i>Internal and Emergency Medicine</i> , 2017, 12, 387-406.	1.0	44
49	Endogenous Secretory RAGE in Obese Women: Association with Platelet Activation and Oxidative Stress. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E1726-E1730.	1.8	43
50	MicroRNA-181b Regulates ALX/FPR2 Receptor Expression and Proresolution Signaling in Human Macrophages. <i>Journal of Biological Chemistry</i> , 2015, 290, 3592-3600.	1.6	37
51	Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration. <i>Thrombosis Research</i> , 2009, 124, 96-100.	0.8	36
52	Obesity-Driven Inflammation and Colorectal Cancer. <i>Current Medicinal Chemistry</i> , 2012, 19, 5837-5853.	1.2	35
53	Platelet Activation Markers in Patients with Peripheral Arterial Disease. <i>Thrombosis and Haemostasis</i> , 1997, 78, 1434-1437.	1.8	35
54	Relative chemokine and adhesion molecule expression in Mediterranean spotted fever and African tick bite fever. <i>Journal of Infection</i> , 2009, 58, 68-75.	1.7	34

#	ARTICLE	IF	CITATIONS
55	Effects of high-amount high-intensity exercise on in vivo platelet activation: Modulation by lipid peroxidation and AGE/RAGE axis. <i>Thrombosis and Haemostasis</i> , 2013, 110, 1232-1240.	1.8	33
56	Demonstration of Rickettsia Conorii-Induced Coagulative and Platelet Activation in vivo in Patients with Mediterranean Spotted Fever. <i>Thrombosis and Haemostasis</i> , 1995, 74, 631-634.	1.8	33
57	Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1999, 42, 2689-2697.	6.7	30
58	Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin. <i>Thrombosis and Haemostasis</i> , 2009, 101, 687-690.	1.8	30
59	Oxidative-induced membrane damage in diabetes lymphocytes: Effects on intracellular Ca ²⁺ homeostasis. <i>Free Radical Research</i> , 2009, 43, 138-148.	1.5	30
60	Correlation between Migraine Severity and Cholesterol Levels. <i>Pain Practice</i> , 2015, 15, 662-670.	0.9	30
61	Relationship between carotid intima-media thickness and non valvular atrial fibrillation type. <i>Atherosclerosis</i> , 2015, 238, 350-355.	0.4	30
62	Thrombin-antithrombin III complexes in type II diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 1992, 6, 7-11.	1.2	29
63	Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients. <i>Blood</i> , 2008, 112, 1085-1090.	0.6	29
64	Oxidative stress and thromboxane-dependent platelet activation in inflammatory bowel disease: effects of anti-TNF- α treatment. <i>Thrombosis and Haemostasis</i> , 2016, 116, 486-495.	1.8	29
65	Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study. <i>Internal and Emergency Medicine</i> , 2018, 13, 651-660.	1.0	29
66	Thromboxane Biosynthesis, Neutrophil and Coagulative Activation in Type IIa Hypercholesterolemia. <i>Thrombosis and Haemostasis</i> , 1995, 74, 1015-1019.	1.8	29
67	Endothelial Perturbation in Cystic Fibrosis. <i>Thrombosis and Haemostasis</i> , 2001, 86, 1363-1367.	1.8	28
68	Inflammation, oxidative stress and platelet activation in aspirin-treated critical limb ischaemia: Beneficial effects of iloprost. <i>Thrombosis and Haemostasis</i> , 2011, 105, 321-328.	1.8	28
69	Enhanced Lipid Peroxidation and Platelet Activation as Potential Contributors to Increased Cardiovascular Risk in the Low HDL Phenotype. <i>Journal of the American Heart Association</i> , 2013, 2, e000063.	1.6	28
70	Decreased plasma endogenous soluble RAGE, and enhanced adipokine secretion, oxidative stress and platelet/coagulative activation identify non-alcoholic fatty liver disease among patients with familial combined hyperlipidemia and/or metabolic syndrome. <i>Vascular Pharmacology</i> , 2015, 72, 16-24.	1.0	25
71	TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus. <i>Internal and Emergency Medicine</i> , 2011, 6, 203-212.	1.0	24
72	Circulating Myeloid-Related Protein 8/14 is Related to Thromboxane-Dependent Platelet Activation in Patients With Acute Coronary Syndrome, With and Without Ongoing Low-Dose Aspirin Treatment. <i>Journal of the American Heart Association</i> , 2014, 3, .	1.6	24

#	ARTICLE	IF	CITATIONS
73	Oxidant stress as a major determinant of platelet activation in invasive breast cancer. <i>International Journal of Cancer</i> , 2017, 140, 696-704.	2.3	24
74	Homocysteine Modulates the CD40/CD40L System. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2182-2190.	1.2	23
75	Antiplatelet agents in the prevention of diabetic vascular complications. <i>Diabetes/metabolism Reviews</i> , 1993, 9, 177-188.	0.4	22
76	Carotid plaque detection improves the predictive value of CHA2DS2-VASc score in patients with non-valvular atrial fibrillation: The ARAPACIS Study. <i>International Journal of Cardiology</i> , 2017, 231, 143-149.	0.8	22
77	Stress-induced salivary cortisol secretion during hypobaric hypoxia challenge and in vivo urinary thromboxane production in healthy male subjects. <i>Stress</i> , 2011, 14, 282-289.	0.8	20
78	Evaluation of mean platelet volume as a predictive marker for cancer-associated venous thromboembolism during chemotherapy. <i>Haematologica</i> , 2014, 99, 1638-1644.	1.7	20
79	Determinants of thromboxane biosynthesis in rheumatoid arthritis: Role of RAGE and oxidant stress. <i>Free Radical Biology and Medicine</i> , 2010, 49, 857-864.	1.3	18
80	Cardiovascular risk and dietary sugar intake: is the link so sweet?. <i>Internal and Emergency Medicine</i> , 2012, 7, 313-322.	1.0	17
81	Aspirin for primary prevention in diabetes mellitus: from the calculation of cardiovascular risk and risk/benefit profile to personalised treatment. <i>Thrombosis and Haemostasis</i> , 2015, 114, 876-882.	1.8	17
82	Influence of Metabolic Control on Thromboxane Biosynthesis and Plasma Plasminogen Activator Inhibitor Type-1 in Non-insulin-dependent Diabetes mellitus. <i>Thrombosis and Haemostasis</i> , 1996, 76, 034-037.	1.8	16
83	Deep venous thrombosis and previous myocardial infarction in mild factor XII deficiency: a risk factor for both venous and arterial thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 27, 348-351.	1.0	15
84	A Complex Interaction between <i>Rickettsia conorii</i> and Dickkopf-1 â€” Potential Role in Immune Evasion Mechanisms in Endothelial Cells. <i>PLoS ONE</i> , 2012, 7, e43638.	1.1	15
85	CD40-CD40L interactions in platelet activation. <i>Thrombosis and Haemostasis</i> , 2005, 93, 1011-1012.	1.8	13
86	Pentraxin 3 and Platelet Activation in Obese Patients After Gastric Banding. <i>Circulation Journal</i> , 2016, 80, 502-511.	0.7	13
87	Mean platelet volume variation after biologic therapy in psoriasis and psoriatic arthritis. <i>European Journal of Dermatology</i> , 2014, 24, 133-135.	0.3	12
88	Estimated Glomerular Filtration Rate Is an Easy Predictor of Venous Thromboembolism in Cancer Patients Undergoing Platinum-Based Chemotherapy. <i>Oncologist</i> , 2014, 19, 562-567.	1.9	8
89	Variability in the response to antiplatelet treatment in diabetes mellitus. <i>Prostaglandins and Other Lipid Mediators</i> , 2012, 98, 48-55.	1.0	7
90	Increased expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental <i>Rickettsia conorii</i> infection. <i>BMC Infectious Diseases</i> , 2014, 14, 70.	1.3	6

#	ARTICLE	IF	CITATIONS
91	Beyond Hyperglycemia in Diabetes: Role of Statin Treatment on Thrombogenesis Triggered by Inflammation. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 281-284.	1.3	3
92	Thromboxane-Dependent Platelet Activation After Gastric Banding for Obesity. <i>JAMA Surgery</i> , 2015, 150, 179.	2.2	3
93	High serum CXCL10 in <i>Rickettsia conorii</i> infection is endothelial cell mediated subsequent to whole blood activation. <i>Cytokine</i> , 2016, 83, 269-274.	1.4	3
94	Soluble CD40L in Mediterranean Spotted Fever: Relation to oxidative stress and platelet activation. <i>Thrombosis Research</i> , 2010, 125, 362-364.	0.8	2
95	Platelets, oxidative stress and preservation of the vascular endothelium: is it a matter of fat?. <i>Internal and Emergency Medicine</i> , 2012, 7, 199-201.	1.0	2
96	Relationship between Factor XII deficiency and thrombosis: the debate is still open?. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 27, 456-457.	1.0	1
97	Platelets and Diabetes. , 2017, , 1225-1238.		1